ARCH Venture Management, LLC Diversified Active

Location: Chicago, IL

CIK: 0001274403 · Show all filings

Period: Q2 2023 (← Previous) (Next →)

Filing Date: Aug 9, 2023

Total Value: $162M (100.0% shares, 0.0% debt)

Holdings (6)

— EQRX, INC. 41.7%

Value $67.58M Shares 36,335,375 Est. Cost $6.82 Unrealized —

— VERVE THERAPEUTICS, INC. 23.3%

Value $37.67M Shares 2,008,809 Est. Cost $36.87 Unrealized —

ERAS ERASCA, INC. 18.8%

Value $30.51M Shares 11,055,554 Est. Cost $17.12 Unrealized -83.4%

DNLI DENALI THERAPEUTICS, INC. 12.6%

Value $20.47M Shares 693,749 Est. Cost $26.20 Unrealized +7.3%

— SINGULAR GENOMICS SYSTEMS, INC. 1.9%

Value $3.153M Shares 3,798,926 Est. Cost $11.56 Unrealized —

— UNITY BIOTECHNOLOGY, INC. 1.6%

Value $2.562M Shares 1,004,817 Est. Cost $0.40 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	EQRX, INC.	36,335,375	$67.58M	41.7%	$6.82	—	COM	26886C107
—	VERVE THERAPEUTICS, INC.	2,008,809	$37.67M	23.3%	$36.87	—	COM	92539P101
ERAS	ERASCA, INC.	11,055,554	$30.51M	18.8%	$17.12	-83.4%	COM	29479A108
DNLI	DENALI THERAPEUTICS, INC.	693,749	$20.47M	12.6%	$26.20	+7.3%	COM	24823R105
—	SINGULAR GENOMICS SYSTEMS, INC.	3,798,926	$3.153M	1.9%	$11.56	—	COM	82933R100
—	UNITY BIOTECHNOLOGY, INC.	1,004,817	$2.562M	1.6%	$0.40	—	COM	91381U200